Table 1.
Pharmacological Treatment Details of the Sample.
| Treatment Characteristic | Mean (SD)/n (%) | ||
|---|---|---|---|
| Treatment prior to inpatient care | |||
| No. of failed adequate SRI trialsa | 2.59 (1.29) | ||
| No. of failed pharmacological augmentation trials | 1.21 (1.03) | ||
| SRI resistance (failed ≥2 adequate SRI trials) | 348 (82.85%) | ||
| Failed 2 augmentation trials (at least 1 antipsychotic) | 134 (31.90%) | ||
| History of poor response to outpatient CBTb | 131 (31.19%) | ||
| Treatment during inpatient care | |||
| Number of days of inpatient care | 42.74 (25.31) | ||
| SRI (mean dose ± SD in mg) | Fluoxetine (71.51 ± 11.97 mg) | 79 (18.57%) | |
| Sertraline (229.11 ± 49.75 mg) | 78 (18.81%) | ||
| Escitalopram (26.03 ± 5.18 mg) | 78 (18.57%) | ||
| Fluvoxamine (280.65 ± 43.75 mg) | 62 (14.76%) | ||
| Clomipramine (183.56 ± 37.92 mg) | 54 (12.86%) | ||
| Venlafaxine (232.69 ± 23.05 mg) | 39 (9.29%) | ||
| Paroxetine (70.24 ± 10.06 mg) | 21 (5%) | ||
| Desvenlafaxine (116.67 ± 28.87 mg) | 3 (0.71%) | ||
| Vilazodone (60 ± 20 mg) | 3 (0.71%) | ||
| No SRI | 3 (0.71%) | ||
| Augmentation (mean dose + SD in mg) | Risperidone (2.72 ± 1.24 mg) | 78 (18.57%) | |
| Aripiprazole (13.37 ± 4.51 mg) | 52 (12.38%) | ||
| Quetiapine (209.38 ± 118.63 mg) | 16 (3.81%) | ||
| Haloperidol (15.75 ± 8.5 mg) | 4 (0.95%) | ||
| Clomipramine (75 mg) | 6 (1.43%) | ||
| Buspirone (30 mg) | 3 (0.71%) | ||
| Ondansetron (4.5 ± 2.33 mg) | 8 (1.9%) | ||
| Granisetron (2 mg) | 2 (0.48%) | ||
| Mirtazapine (15 mg) | 2 (0.48%) | ||
| Memantine (20 mg) | 5 (1.19%) | ||
| N-Acetyl cysteine (2200 ± 346.41 mg) | 3 (0.71%) | ||
| Lamotrigene (200 mg) | 2 (0.48%) | ||
| Any augmenting agent | 175 (41.47%) | ||
| Concomitant Anxiolytic/Sedatives (mean dose + SD in mg) | Clonazepam (0.98 ± 0.60 mg) | 133 (31.67%) | |
| Pregabalin (235 ± 117.73 mg) | 31 (7.38%) | ||
| Zolpidem (10 mg) | 16 (3.81%) | ||
| Lorazepam (2 mg) | 10 (2.38%) | ||
| Trazodone (125 ± 50 mg) | 8 (1.9%) | ||
| Management during follow-up (n = 330) | |||
| Length of follow-up in months | 25.12 (17.06); median = 21 | ||
| Readmission | 56 (13.33%) | ||
| Outpatient CBT (“booster CBT”) | 42 (10%) | ||
| Medication management summary | No change | 125 (37.88%) | |
| Change to another SRI/clomipramine | 45 (13.64%) | ||
| Change/addition of augmenting agent only | 77 (23.33%) | ||
| Both SRI change and subsequent augmentation | 83 (25.15%) | ||
Note. N = 420. SRI = serotonin reuptake inhibitor.
a Defined as completed 8 to 12 weeks at adequate dosing in accordance with APA/IJP Clinical Practice Guidelines.
b Completed at least 10 sessions of outpatient-based cognitive behavioral therapy (CBT).